Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma
Authors:
Open Access
- 21 December 2024
- journal article
- research article
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 33 (1) , 200927
Abstract
No abstract availableKeywords
Funding Information
- Children's Cancer Foundation
- Pediatric Cancer Research Foundation
- Children's Cancer Foundation
- National Institutes of Health (1U54 CA232561-01A1)
This publication has 26 references indexed in Scilit:
- Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapyExpert Opinion on Therapeutic Targets, 2015
- Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG MiceCancer Immunology Research, 2015
- Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II StudyJournal of Clinical Oncology, 2012
- Innate or Adaptive Immunity? The Example of Natural Killer CellsScience, 2011
- Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell CarcinomaJournal of Clinical Oncology, 2008
- NeuroblastomaThe Lancet, 2007
- IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trialBone Marrow Transplantation, 2003
- IL-21 in Synergy with IL-15 or IL-18 Enhances IFN-γ Production in Human NK and T CellsThe Journal of Immunology, 2003
- Cutting Edge: The Common γ-Chain Is an Indispensable Subunit of the IL-21 Receptor ComplexThe Journal of Immunology, 2001
- Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte functionNature, 2000